Melanoma in Strasbourg University Hospital. A 30 year study;Le melanome au C.H.U. De Strasbourg. Etude sur 30 ans

Annales de Dermatologie et de Venereologie

Volumn 125, Issue 4, 1998, Pages 241-246

  Lipsker, D ^a   Heid, E ^a   Grosshans, E ^a   Cribier, B ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER SURGERY; EARLY DIAGNOSIS; FEMALE; FRANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; RETROSPECTIVE STUDY; SCHOOL CHILD; SURVIVAL RATE; DIFFERENTIAL DIAGNOSIS; MIDDLE AGED; PROGNOSIS; SKIN TUMOR; STATISTICS; TIME; UNIVERSITY HOSPITAL;

ADULT; AGED; DIAGNOSIS, DIFFERENTIAL; FEMALE; FRANCE; HOSPITALS, UNIVERSITY; HUMANS; MALE; MELANOMA; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; TIME FACTORS;

EID: 0032038529     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Boyle P, Maisonneuve P, Doré JF. Epidemiology of malignant melanoma. Br Med Bull 1995;51:523-47.
2. Achten G, André J. Le mélanome: quelques chiffres. Ann Dermatol Venereol 1993:120:643-8.
3. Estève J, Kicker A, Ferlay J, Parkin DM. Facts and figures of cancer in the European Community. IARC, Lyon, France, 1993.
4. Van der Esch, Muir CS, Nectoux J, Macfarlane G, Maisonneuve P, Bharucha H et al. Temporal change in diagnostic criteria as a cause of the increase of malignant melanoma over time is unlikely. Int J Cancer 1991;47:483-9.
5. Bagley FH, Cady B, Lee A, Legg MA. Changes in clinical presentation and management of malignant melanoma. Cancer 1981;47:2116-23.
6. Shafir R, Hiss J, Tsur H, Bubis JJ. The thin malignant melanoma: changing patterns of epidemiology and treatment. Cancer 1982;59:817-22
7. Balch CM, Soong SJ, Shaw HM, Maddox WA, Urist UM, McCarthy WH et al. Changing trends in the clinical and pathologic features of melanoma. In : Balch CM, Houghton AN, Milton GW, Sober AJ, Soong SJ (eds): Cutaneous Melanoma. Philadelphia, JB Lippincott Company 2nd ed, 1992, pp 40-5.
8. Masback A, Westerdahl J, Ingvar C, OIsson H, Jonsson N. Cutaneous malignant melanoma in South Sweden 1965, 1975 and 1985 - a histopathologic review. Cancer 1994:73:1625-30.
9. Herd RM, Cooper EJ, Hunter JAA, McLaren K, Chetty U, Watson ACH et coll. Cutaneous malignant melanoma. Publicity, screening clinics and survival - the Edinburgh experience 1982-90. Br J Dermatol 1995:132:563-70.
10. Swerlick RA, Chen S. The melanoma epidemic. Is increased surveillance the solution or the problem ? Arch Dermatol 1996:132:881-4.
11. Baccard M, Chevret S, Chemaly P, Morel P. Délai de diagnostic du mélanome. Etude prospective chez 102 malades. Ann Dermatol Venereol 1997;124:601-6.
12. Armstrong BK, English DR. Epidemiologic studies. In Balch CM, Houghton AN, Milton GW, Sober AJ, Soong SJ (eds): Cutaneous Melanoma (eds). Philadelphia, JB Lippincott Company 2nd ed, 1992, pp 12-26.
13. Rompel R, Weiss H, Zöfel P, Petres J. Epidemiologie des malignen Melanoms in Stadt- und Landbevölkerung. Z Hautkr 1997;72:29-33.
14. Van der Spek-Keijser LMT, Van der Rhee HJ, Tom G, Van Westering R, Bruijn JA, Coebergh JWW. Site, histological type, and thickness of primary cutaneous melanoma in western Netherlands since 1980. Br J Dermatol 1997:136:565-71.
15. Balch CM, Soong SJ, Shaw HM, Urist MM, McCarthy WH. An analysis of prognostic factors in 8500 patients with cutaneous melanoma. In Balch CM, Houghton AN, Milton GW, Sober AJ, Soong SJ (eds): Cutaneous Melanoma. Philadelphia, JB Lippincott Company 2nd ed, 1992, pp 165-87.
16. Gamel J, George S, Stanley W. Skin melanoma, cured fraction time and survival time as functions of thickness, site, histologic type, age and sex. Cancer 1993:72:1219-23.
17. Garbe C, Orfanos CE. Epidemiology of malignant melanoma in central Europe: risk factors and prognostic predictors. Results of the central malignant melanoma registry of German Dermatological Society. Pigment cell Res 1992;2:285-94.
18. Keefe M, MacKie RM. The relationship between risk of death from clinical stage I cutaneous melanoma and thickness of primary tumor: non evidence for steps in risk. Br J Cancer 1991;64:598-602.
19. Soong S, Shaw H, Balch C, McCarthy WH, Urist MM, Lee JY. Predicting survival and recurrence in localized melanoma: a multivariate approach. World J Surg 1992;16:91-5.
20. Balch CM, Houghton AN. Diagnosis of metastatic melanoma at distant sites. In : Balch CM, Houghton AN, Milton GW, et al (eds): Cutaneous Melanoma. Philadelphia, JB Lippincott company 2nd ed, 1992, pp 439-67.
21. Markowitz JS, Cosimi LA, Carey RW, Kang S, Padyk C, Sober AJ et al. Prognosis after initial recurrence of cutaneous melanoma. Arch Surg 1991:126:703-8.
22. Kelly JW, Blois MS, Sagebiel RW. Frequency and duration of patient follow-up after treatment of a primary malignant melanoma. J Am Acad Dermatol 1985:13:756-60.
23. Mundth ED. Malignant melanoma: a clinical study of 427 cases. Ann Surg 1965:162:15-21.
24. Avril MF, Nguyen T, Duvillard P, Bognel C, Margulis A. Récurrences tardives de mélanomes au-delà de JOans. Ann Dermatol Venereol 1994:121:454-8.
25. Rogers OS, Kopf AW, Rigel DS, Friedman RJ, Levenstein M, Bart RS. Hazard-rate analysis in stage I malignant melanoma. Arch Dermatol 1986:122:999-1002.
26. Eggermont AMM. Surveillance des malades atteints de mélanomes de stade I après exérèse de la tumeur primitive. Ann Dermatol Venereol 1995:122:292-7.